Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guanosine‐2',3'‐O‐ethylidenephosphonate is a synthetic small molecule analog of guanosine in which the ribose moiety is protected at the 2' and 3' positions by an ethylidene group and a phosphonate group replaces the natural phosphate linkage. It acts as an inhibitor of purine nucleoside phosphorylase (PNP), an enzyme involved in purine metabolism. This compound has been studied primarily as a biochemical probe or experimental tool for investigating PNP function and nucleotide metabolism but has not advanced to clinical development or approval for any therapeutic indication[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guanosine-2',3'-O-ethylidenephosphonate.